Introduction
Polo-like kinases (Plks), which comprise a family of serine/threonine kinases, are highly conserved from yeasts to humans (Hamanaka et al., 1994) . This family includes mammalian Plk1, Plk2 (serum-inducible kinase (Snk)), and Plk3 (fibroblast growth factor-inducible kinase (Fnk)/proliferation-related kinase (Prk)), Plk4 (Sak), Xenopus laevis Plx1, Drosophila melanogaster polo, Schizosaccharomyces pombe (fission yeast) Plo1, and Saccharomyces cerevisiae (budding yeast) Cdc5. These enzymes in addition to a conserved kinase domain at the N-terminus have highly conserved sequences of 30 amino acids, called polo-box(s) in the noncatalytic Cterminal domain (Glover et al., 1998) . A polo-box mutant of Plk1 that does not affect its kinase activity but abolishes its subcellular relocalization is capable of abolishing its biological activity in vivo (Lee et al., 1998 (Lee et al., , 1999 . These findings suggest that polo-box of Plk1 plays a critical role for Plk1 function, especially for its spatial distribution and physical interaction with substrates. Genetic and biochemical experiments in various organisms indicate that plks are important regulators of many cell-cycle-related events, including bipolar spindle formation (Hamanaka et al., 1995; Glover et al., 1996) , chromosome segregation, centrosome maturation in late G2/early prophase (Lane and Nigg, 1996) , activation of Cdc2, regulation of anaphase-promoting complex, and execution of cytokinesis (Lane and Nigg, 1996; Glover et al., 1998; Nigg, 1998) . It is predominantly cytoplasmic during interphase but is associated with condensed chromosomes during mitosis (Llamazares et al., 1991) when its kinase activity is also at its peak (Fenton and Glover, 1993) . It has been demonstrated that Plk1 mRNA expression is low at the G1/S transition, increases during S phase, and is maximally expressed during G2/M. The report of Kumagai and Dunphy (1996) suggests that Plx1 is a critical trigger that initiates the onset of the G2/M transition through activating cdc25. During the metaphase-anaphase transition, Plx1 is required for the destruction of targets of the anaphase-promoting complex (APC) that drives mitotic exit (Descombes and Nigg, 1998) . Conversely, in myeloid leukemia cell lines undergoing terminal differentiation, Plk1 expression is drastically reduced (Yuan et al., 1997) .
Plk1 has been suggested to directly phosphorylate components of APC including Cdc27 and activate the latter (Kotani et al., 1998) . Intranuclear Plk1 together with other signal proteins (p34 kinase, cyclin B, etc.) is responsible for mitotic progression. Increasing evidences support the concept that Plks regulate pivotal stages throughout mitosis including its initiation by activating Cdc2 through Cdc25 and direct phosphorylation of cyclin B1 targeting Cdc2/cyclin B1 to the nucleus (Glover et al., 1998; Nigg, 2001 ). In addition, in a previous study (Shimizu and Osada, 2000) , the level of Plk1 mRNA in cancer cells was associated with the extent of its interaction with heat-shock protein 90. Plk1-dependent phosphorylation of BRCA2 is enhanced during mitotic progression, or inhibited by DNA damage, suggesting that it serves to coordinate biological processes in which BRCA2 participates (Lee et al., 2004) . Still, recent data support a regulatory role of the mammalian Plk1 at the cell cycle G2 checkpoint (Smits et al., 2000; vanVugt et al., 2001) , although the finding that Cdc25c À/À mice did not display any obvious abnormalities in cellular response to DNA damage nor Plk1 has been closely linked to cellular proliferation. Therefore, it is not hard to imagine that Plk families could be associated with cancer development and progression. As a matter of fact, overexpression of murine Plk1 in NIH3T3 cells confers a transformed phenotype, which is manifested as foci capable of growth in soft agar and formation of tumors in nude mice (Smith et al., 1997) . It was further shown that cells isolated from the excised tumors continued to overexpress the Plk1 protein, and many of these cells were multinucleated (Fisher and Ferris, 2002) . As mentioned above, the expression and function of Plk1 have been analysed in cell lines from the viewpoint of physiological or pathological roles in vitro. In addition, Plk1 and Plk3 expressions have been widely examined in tumors from the cancer patients.
Results from these studies indicate that overexpression of Plk1 is positively correlated with aggressiveness and prognosis in many cancers. In contrast, Plk3 is downregulated in carcinomas of the lung (Li et al., 1996) , head and neck , and the colon . Moreover, inhibition of Plk1 with various techniques results in growth arrest or apoptosis for the cancer cells. Thus, Plk1 could be a novel prognostic marker and a good target for chemotherapeutic intervention.
Non-small-cell lung cancer (NSCLC)
NSCLC patients whose tumors showed moderate Plk1 expression survived significantly longer (5-year survival rate ¼ 51.8%) than those with high levels of Plk1 transcripts (24.2%, P ¼ 0.001) using Northern blot experiments. The prognosis of patients in postsurgical stages I and II was correlated with Plk1 expression (5-year survival rates in stage I: 69.1% (moderate Plk1)-43.5% (high Plk1), P ¼ 0.03 or in stage II: 51.9% (moderate Plk1)-9.9% (high Plk1), P ¼ 0.006) (Wolf et al., 1997) .
Head and neck cancer
A total of 89 head and neck squamous cell carcinomas (HNSCC) patients were analysed, and HNSCC patients with moderate Plk1 transcript levels survived significantly longer than those with high Plk1 transcripts (5-year survival rates, 43 versus 12%; P ¼ 0.0047) (Knecht et al., 1999) .
Later, they demonstrated again that Plk1 protein was overexpressed (median ¼ 69.4%, minimum ¼ 22.3%, maximum ¼ 74.8%) in 157 oropharyngeal carcinomas (P ¼ 0.016). A correlation of Plk1 expression with clinicopathological parameters led to further significant correlations with pathological tumor stage (P ¼ 0.007) and pN stage (P ¼ 0.012) but not with N stage (P ¼ 0.09). A Kaplan-Meier analysis based on a median cutoff showed that patients exhibiting moderate Plk1 expression (o59.4%) had longer survival times than those exhibiting high expression (X59.4, P ¼ 0.013) (Knecht et al., 2000) .
Esophageal and gastric cancer
Patients with esophageal carcinomas having a high level of Plk1 expression had a significantly poorer survival rate than those with low level of Plk1 expression (3-year survival rates, 54.9 versus 24.8%, Po0.05) in 49 patients. On the other hand, 55 gastric carcinomas (73%) of 75 patients were revealed to overexpress Plk mRNA, but the expression status showed no correlation with prognosis (Tokumitsu et al., 1999) .
Melanomas
Elevated Plk1 expression (median, 52.9%; mean, 54.3%; range, 3.9-98.5%) was observed in the 175 samples of melanoma. Furthermore, Plk1 positivity varied with tumor thickness. Based on a median cutoff, the KaplanMeier analysis revealed that patients with moderate versus high Plk1 expression survived significantly longer (10-year survival rates, 93.6 versus 84.9%; P ¼ 0.03) .
Malignant melanomas with metastases expressed Plk1 at markedly elevated levels compared to melanomas without metastases (median, 60.00 versus 37.98%; P ¼ 0.000053) (Kneisel et al., 2002) .
Breast cancer
Analysis of the immunohistochemical data from 30 breast cancer patients revealed a close correlation between the estrogen receptor (ER) and Plk1 expression (r ¼ 0.677; P ¼ 0.001). No relationship between the mRNA expression of ER and MIB-1 exists (Wolf et al., 2000) .
Ovarian cancer
In tumor tissue from 17 patients with ovarian carcinoma, the percentage of Plk1-stained cells was 13.5475.19% (Takai et al., 2001a) .
In another report, the tissue specimens of normal ovaries (n ¼ 9), cystadenomas (n ¼ 17), borderline tumors (n ¼ 13), and ovarian carcinomas (n ¼ 77) were evaluated. The overexpression of Plk1 had an impact on patient prognosis with shortened survival time for patients with tumors positive for Plk1 (P ¼ 0.02), and Plk1 expression remained a prognostic factor in multivariate survival analysis (P ¼ 0.03) (Weichert et al., 2004) .
Endometrial cancer
In tumor tissue from 20 patients with endometrial carcinoma, the percentage of Plk1-stained cells was 13.4874.86% in grade 1, 17.5176.71% in grade 2, and 38.6271.50% in grade 3, respectively. The number of Plk1-positive cells was significantly higher in endometrial carcinomas designated as grade 3 than in carcinomas designated as grade 1 and 2 (Po0.0001) (Takai et al., 2001b) .
Colorectal cancer
Plk1 mRNA levels were measured in 70 colorectal specimens, evaluating both tumor tissues and paired normal mucosa. Levels of Plk1 expression in tumor relative to paired normal mucosa correlated directly with patient age and with each other but did not correlate with tumor stage. These results suggest a mechanism for augmented disruption of mitotic regulation in older patients (Macmillan et al., 2001) .
Another study demonstrated that elevated expression of Plk1 was observed in 57 (73.1%) of 78 primary colorectal cancers, statistically significant associations being evident with pT (primary tumor invasion) (P ¼ 0.0006), pN (regional lymph nodes) (P ¼ 0.008), and the Duke's classification (P ¼ 0.0005) (Takahashi et al., 2003) .
Gliomas
A total of 48 malignant gliomas and 20 benign gliomas were compared. Plk1 labelling increased in glial tumors in correlation with higher grades of anaplasia (Po0.05). Nearly all tumor cells showed an intense immunostaining, although the Plk1 expression varied among the individual glioblastoma cells. In addition, a positive correlation with a correlation coefficient of r ¼ 0.519 (Po0.05) between the immunolabelling of Plk1 and MIB-1 was calculated (Dietzmann et al., 2001) .
Thyroid cancer
In follicular tumors and anaplastic carcinoma, Plk1 overexpression was not a common event and only 5.9% of follicular adenoma, 7.1% of follicular carcinoma, and 11.8% of anaplastic carcinoma overexpressed this protein. However, 43.7% of papillary carcinoma overexpressed Plk1. Plk1 overexpression was more frequently observed in smaller papillary carcinoma lesions, and 62.5% of microadenoma (ranging from 4 to 10 mm) and even 66.7% of incidental carcinoma o4 mm) overexpressed it, whereas this phenomenon could only be seen in 20.0% of lesions larger than 40 mm. These findings suggest that, unlike other carcinomas previously studied, Plk1 plays a constitutive role in papillary carcinoma especially in the early phase, and may contribute to the malignant transformation of this carcinoma (Ito et al., 2004) .
Plk3 and cancers
Mammalian Plk3 (alternatively named Prk (Li et al., 1996) and Fnk (Donohue et al., 1995) ) was originally shown to be an immediate early gene product. While initially linked to G1 phase, Plk3 protein can be detected throughout the cell cycle and, similar to Plk1, is actually found at its highest levels and activity from late S phase through M phase. Furthermore, in correlation with its activity, Plk3 is phosphorylated following growth stimulation and maximally during M phase (Chase et al., 1998) . Plk3, as well as Plk1, is capable of rescuing CDC5 temperature-sensitive (ts) mutants at restrictive temperature, indicating functional conservation of these kinases throughout evolution (Lee and Erikson, 1997; Ouyang et al., 1997) . In contrast to Plk1, several studies have observed that Plk3 expression is negatively correlated with the development of certain cancers, despite its original description as an immediate early gene inducible by serum and cytokines (Li et al., 1996) . Plk3 mRNA is either undetectable or markedly downregulated in lung carcinomas compared with the uninvolved 'normal tissues' of the same patients (Li et al., 1996) . Several polymorphisms were identified in 40 lung tumor cell lines examined, although neither missense nor nonsense mutations were detected (Wiest et al., 2001) , suggesting that mutational inactivation of the coding sequence of the Plk3 gene is a rare event in lung cancer. The abundance of Plk3 mRNA is similarly reduced in HNSCC and in carcinogeninduced rat colon tumors . Consistent with these observations, ectopic expression of Plk3, but not that of a truncated, kinase-inactive mutant of this protein, reduces the rate of fibroblast cell proliferation in vitro . Furthermore, enforced expression of constructs expressing kinase-active Plk3 induces the condensation of chromatin, rapid cell cycle arrest and apoptosis (Conn et al., 2000; Wang et al., 2002) .
Inhibition of Plk1
The use of different methods to abrogate the activity of Plk1 revealed its essential role for mitotic progression in and Nigg, 1996) . Antisense oligodeoxynucleotides (ODNs) to Plk1 have also been shown to be effective for inhibition of its expression in tumor cell lines, leading to loss of cell viability and even demonstrating an antitumor activity in A549 xenografts (Elez et al., 2000) . Results from transient expression of dominantnegative Plk1 differed from previous antibody microinjection experiments in that most of the mitotic HeLa cells were bipolar and cytokinesis seemed to be disrupted (Mundt et al., 1997) . Expression of dominant-negative Plk1 via an adenoviral vector induces programmed cell death in most tumor cells but not in normal human mammary epithelial cells (Conn et al., 2000) . Polo-box, located in C-terminal region of Plk1, is thought to be important for subcelluar localization and interaction with substrate proteins. Yuan et al. have made fusion peptides of the polo-box with the homodomain of antennapedia to be internalized into cells. Membrane-permeable polo-box peptides inhibit cancer cell proliferation efficiently (Yuan et al., 2002) . Overexpression of a kinase-inactive form of mammalian Plk1 in most tumor cell lines was shown to induce a centrosome maturation defect in combination with mitotic catastrophe and apoptosis (Cogswell et al., 2000) . Recently, a small interfering RNA (siRNA) technique has been developed to delete a specific mRNA. About half of the cells transiently treated with Plk1 siRNA arrest at G2/M with 4 N DNA content in FACS profiles and show the formation of a dumbbelllike DNA organization, suggesting that sister chromatids are not completely separated (Liu and Erikson, 2002) . Plk1 depletion for extended period by vectorbased siRNA caused cell cycle arrest at mitosis and apoptosis in several cancer cells lines Erikson, 2002, 2003; Spankuch-Schmitt et al., 2002) . Moreover, the p53 pathway is shown to be involved in the apoptosis induced by Plk1 depletion (Liu and Erikson, 2003) .
Scytonemin, a yellow green pigment found only in the extracellular sheath of cyanobacteria, has been reported to be a low micromolar inhibitor of Plk1 that blocks proliferation of multiple cell types including rheumatoid synovial fibroblasts, normal human lung fibroblasts, human umbilical vein endothelial cells, and Jurkat cells (Stevenson, 1999) . The expression of Plk1 decreases following inhibition of PLCg and PI3-kinase (Dietzmann et al., 2001) . Expression of the Plk1 gene was significantly suppressed by b-hydroxyisovalerylshikonin (b-HIVS) in U937 and HL60 cells (Masuda et al., 2003) . Treatment with Plk1-specific antisense ODNs sensitized K562 cells to b-HIVS-induced apoptosis, indicating that suppression of the expression and activity of Plk1 by b-HIVS is involved in apoptosis (Masuda et al., 2003) .
Conclusive remarks
There is no Plk1 expression in most differentiated cells in contrast to tissues with proliferative potential such as placenta Yoshimatsu et al., 1999) , endometrium (Takai et al., 2000) , and cancers. The expression of Plk1 is strongly correlated with aggressiveness and prognosis in many cancers. Therefore, Plk1 could be used as a novel diagnostic marker for several types of cancers, and inhibition of Plk1 function could be an important application for cancer therapy. To date, several techniques and compounds to inhibit Plk1 have been identified and appear to be promising. In the future, methods for inhibition of Plk1 could be improved and applied in treatment of cancer patients.
